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Cancer stem cells (CSC) which have been identified in several tumors, including liver
cancer, represent a particular subpopulation of tumor cells characterized by properties
similar to those of adult stem cells. Importantly, CSC are resistant to standard therapies,
thereby leading to metastatic dissemination and tumor relapse. Given the increasing
evidence that iron homeostasis is deregulated in cancer, here we describe the iron
homeostasis alterations in cancer cells, particularly in liver CSC. We also discuss two
paradoxically opposite iron manipulation-strategies for tumor therapy based either on
iron chelation or iron overload-mediated oxidant production leading to ferroptosis. A
better understanding of iron metabolism modifications occurring in hepatic tumors and
particularly in liver CSC cells may offer new therapeutic options for this cancer, which is
characterized by increasing incidence and unfavorable prognosis.
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INTRODUCTION
The phenotypical and functional heterogeneity of cells within tumors can be explained by both the
conventional mechanism centered on clonal evolution and amodel based on the presence of cancer
stem cells (CSC) which over the last decade received support by increasing experimental evidence.
CSC have similar properties to adult stem cells, such as the ability for unlimited self-renewal and
differentiation and are believed to be a major source of cancer initiation and progression, thus
resulting in a heterogeneous tumor cell progeny (1–3). Moreover, CSC are characterized by drug
resistance, an element allowing tumors to survive therapies. In fact, the relatively quiescent CSC can
escape cell death after standard chemotherapy treatments, which preferentially eliminate rapidly
proliferating cells; as a consequence, the remaining CSC may lead to cancer relapse and metastasis,
whose treatment is more complex and often unsatisfactory. Notably, it is now also realized that
some of the alterations of iron homeostasis that have recently emerged as key factors in cancer
growth and progression are present also in CSC [reviewed in (4)]. In this Review, we discuss current
knowledge of the role of iron as a key factor in cancer development, particularly in liver and hepatic
CSC, and we also address iron-centered therapeutic approaches.
PRIMARY LIVER CANCER AND CANCER STEM CELLS
Primary liver cancer (PLC) is the fifth most common cancer worldwide and the second
most frequent leading cause of cancer-related mortality and its incidence and mortality are
increasingat a fast rate, especially in western countries (5, 6). Hepatocellular carcinoma (HCC) and
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cholangiocarcinoma (CCA) represent the two major forms of
PLC, and account for ∼ 90 and 5% of all primary liver tumors,
respectively (5, 6).
HCC arises from malignant transformation of hepatocytes
and is often associated with known risk factors, such as excessive
alcohol intake, infection with hepatitis B virus (HBV) or
hepatitis C virus (HCV), aflatoxin B1 intake, fatty infiltration,
autoimmune liver diseases and alterations of iron metabolism
leading to hepatic iron accumulation like hemochromatosis (5,
7). Unlike the HCV-related HCCs, the incidence of HCC linked
to the metabolic syndrome is increasing, principally due to
obesity epidemic continuous rising (8).
On the other hand, CCA arise from neoplastic transformation
of intra- and extra-hepatic biliary epithelial cells (cholangiocytes)
and the frequency of its established risk factors mostly differs
depending on geographic area (9). For example, infection with
liver flukes (Opisthorchis viverrini and Clonorchis sinensis) is a
common risk factor for CCA development in Southeast Asia
(6, 10). Conversely, primary sclerosing cholangitis (PSC) is the
most common predisposing condition for CCA in the western
countries (6). HBV orHCV infection and cirrhosis have been also
proposed as potential etiologies of CCA, shared with HCC (6, 7).
While liver transplantation, surgical resection and
locoregional therapies are possible curative options at early
phases, the majority of PLC patients unfortunately present
advanced stages of the disease, for which treatments are very
limited and the prognosis remains unfavorable (5, 11).
Like most other solid tumors, PLC are characterized by an
extensive clinical and pathobiological heterogeneity in terms
of cellular morphologies as well as genetic and epigenetic
landscape (12–14). Such intra-tumor heterogeneity may reflect
the presence of different clonal subpopulations exhibiting
differential sensitivity to drugs (7, 12, 13). In this respect, the
recent advent of the CSC hypothesis has added a new level
of complexity in understanding PLC heterogeneity and drug
resistance. According to this model, CSC are thought to drive
tumor growth and progression, as well as tumor metastasis,
recurrence and therapy resistance, representing the unique
unit of selection within the tumor (2, 15–17). Interestingly,
a new “CSC plasticity model” has been proposed, further
increasing the complexity of tumor biology. According to this
theory, the different tumor cell subpopulations are highly plastic
and dynamic, continuously switching between non-CSC and
CSC phenotypes, depending on various intrinsic and extrinsic
stimuli (18).
While the CSC existence has been confirmed in HCC (19–22)
and recently also in CCA (23, 24), no consensus has yet been
reached regarding the origin of hepatic CSC. In addition to the
classical idea that CSC originate from normal liver resident stem
cells (1), it is now become accepted that CSC may originate also
from more committed progenitor cells and mature differentiated
tumor cells through a reprogramming process (11, 25, 26). These
considerations go hand in hand with the unsettled debate about
the true nature of the PLC cell-of-origin, about which a consensus
has not been reached, yet.
Another open question concerns the identification of a
common recognized method for isolation and subsequent
characterization of liver CSC. During the last years several
attempts have been made to obtain a cell population enriched in
liver CSC using a variety of techniques. The antigenic approach,
which is one of the first methods used to isolate CSC, relies on
surface CSC markers detection, including CD133, CD44, OV6,
CD90, EpCAM, CD13, CD24, CD47 (27). However, the antigenic
approach has several shortcomings, such as lack of clearly defined
surface markers specific for individual tumor type, such as
PLC, and the fact that different cancer cell populations with
tumor-initiating activity can be isolated using different markers
within a tumor type (18, 28). Therefore, none of the proposed
markers is specific for liver CSC and universally expressed in all
liver CSC (29). In addition, the surface marker expression can
diverge depending on the specific context (28). In addition to
the classical antigenic approach, there are several assays based
on CSC functional properties, including Side Population (SP)
analysis, Aldefluor assay and tumor-sphere formation assay (14,
24, 27). All these functional techniques are based on different
key CSC features: the first one on the typical drug resistance of
CSC (30, 31), the second one on the measurement of aldehyde
dehydrogenase activity (32) and the last one on long-term self-
renewal capability of CSC (21, 24, 33). Possibly, a combinatorial
strategy might be a valid alternative to isolate a better-
defined PLC stem-like subset, but the gold-standard approach
to evaluate CSC tumorigenic potential remains the in vivo
approach based on xenotransplantation in immune-deficient
mice (14, 24, 27).
IRON AND LIVER CANCER
Iron is an essential component of living organisms, as it
is necessary for cellular metabolism, replication and growth.
However, excess iron can facilitate the generation of the most
reactive and toxic forms of oxidants through the Fenton reaction
(34); therefore, iron levels are carefully kept within an optimal
range at both systemic and cellular levels (Figure 1). The
major players in maintaining cellular iron homeostasis are the
transferrin receptor (TfR1) that internalizes transferrin-bound
iron, ferroportin (Fpn), the only cellular iron exporter, and
ferritin that stores excess iron (35) (Figure 2). A number of
epidemiological studies indicate a positive association between
cancer and high body iron content in the general population (36).
Since the liver is the organ where excess iron accumulates (37)
and plays an important role in maintaining iron homeostasis, a
large body of evidence from human, animal, and in vitro studies
supports the positive relation between increased body iron stores
and the risk of liver cancer. In fact, HCC is the prevalent tumor
found in hemochromatosis patients (38).
Studies investigating cancer risk in subjects undergoing blood
transfusion or phlebotomy suggest that iron excess is not merely
associated with cancer but plays an active role in carcinogenesis.
The biological basis of the association between iron and cancer is
double-face as it probably rests in both oxidative stress-mediated
DNA damage and availability of the metal to support fast growth
(39). Ironmay therefore play a role both as an initiator in an early
phase and, once malignant change has occurred, as a promoter
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FIGURE 1 | Iron threshold concept. Certain iron levels are required for cell
survival and homeostasis, but iron concentrations too low lead to apoptotic
cell death, whereas excess iron equally triggers cell death.
FIGURE 2 | Cellular iron pathways in a nutshell. Transferrin bound iron,
internalized through endocytosis of the transferrin receptor (TfR1), enters a
pool of redox-active iron whose concentration is kept under control by
mechanisms ensuring that the iron which is not used for biochemical
processes, particularly in mitochondria, is either safely stored in cytoplasmic
ferritin or exported by ferroportin.
that allows the transformed cell to fully express its potential of
unrestricted growth.
In addition, recent studies showed that both systemic and
cellular iron metabolism is altered in tumors (40). In general,
given the high iron needs of tumor cells to sustain cell
proliferation, the alterations of iron trafficking in cancer cells
lead to iron acquisition. To this purpose, cancer cells usually
increase iron uptake, for example by up-regulating TfR1, decrease
iron release by inhibiting Fpn, or both. Several studies have
demonstrated that these alterations of cellular iron metabolism
are directly dependent on the action of oncogenes and tumor
suppressors (39). Notably, the “iron addiction” of tumors was
confirmed by the analysis of different cell lines using a novel
method (41), which showed that cancer cells had significantly
increased redox-active iron pools compared to non-tumorigenic
cells. The role of iron in cancer is not related only to the “iron
seeking” phenotype of most cancer cells. In fact, iron levels can
modulate apoptosis in multiple ways, for example by affecting
the alternative splicing of Fas/CD95 transcripts between the
pro-apoptotic and anti-apoptotic isoforms (42). Moreover, the
p53 pathway that regulates cell cycle and apoptosis interacts
with iron metabolism in a complicated crosstalk that remains
to be completely explained (43). As an example of opposing
observations regarding the involvement of iron and p53 in
the pathogenesis of HCC, it has been shown that exposure to
iron down-regulated MDM2, the ubiquitin ligase which leads to
degradation of p53 (44), whereas another study found decreased
p53 protein levels in the liver of iron overloaded mice (45).
Iron metabolism has been investigated in rodent models of
hepatic carcinogenesis as well as in regenerating liver, which
represents an excellent example of controlled liver proliferation
and hence a powerful model system to get insights into the
processes leading to hepatocarcinogenesis. Similarly to other
types of growing cells, increased expression of TfR1 has been
found in rat liver preneoplastic nodules and HCC (46, 47), as
well as in regenerating liver cells (48), probably in order to insure
sufficient iron to sustain cell proliferation. Recently, a study
investigating iron metabolism gene expression and prognostic
features of HCC found that TfR1 are more expressed in HCC
than in surrounding liver and correlate with poorer prognosis
(49). Researches also addressed the role of iron in CCA, a severe
liver tumor with limited therapeutic possibilities, concluding
that high expression of TfR1, with consequent iron uptake,
contributes to CCA progression and poorer clinical outcomes
(50). Accordingly, we showed that elevated iron content is a
negative prognostic factor in CCA patients (51).
However, recent studies indicated that altered expression of
proteins of iron metabolism like TfR1 in tumor cells is not
only a system to acquire more iron but may impinge on tumor
growth in an iron-independent manner. In fact, in line with
the demonstrated interaction of TfR1 with ligands other than
transferrin (Tf) (52), it appears that, in addition to its role
in iron uptake, TfR1 activates signaling pathways and has a
role in apoptosis, a key process in cancer development. For
example, TfR1, by activating JNK upon phosphorylation by
Src, impairs apoptosis and thereby increases breast cancer cell
survival (53). In addition, the interaction of TfR1 with Tf may
also have roles which are different from iron uptake but are
still important for tumor cell growth; in fact TfR1 appears
to be implicated in epithelial mesenchymal transition (EMT)
(54), which is an important process for cancer progression, and
metastatic growth (55).
Over the last years, a number of studies have shown that the
levels of Fpn are reduced in several cancer cells compared to
their nonmalignant counterparts, so that Fpn downregulation
appears as a common strategy that a variety of cancer cells adopt
to enhance intracellular iron availability (39). Interestingly, Fpn
expression is a strong and independent predictor of prognosis
in different tumor types (39). Dysregulation of the hepcidin/Fpn
axis may also play a relevant role in liver tumors. Recently,
it has been shown that hypermethylation of specific sequences
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in the promoter region of the gene coding for hepcidin, the
liver hormone that regulates iron homeostasis by inhibiting Fpn-
mediated iron export, results in transcriptional downregulation
of hepcidin expression in HCC (56). A similar effect was found in
a model of rat liver carcinogenesis, in which the downregulation
of hepcidin and the consequent increase of Fpn-mediated iron
release may underlie the decreased intracellular levels of iron in
preneoplastic foci (57). This could be a specific feature of hepatic
cancer, as Fpn is usually repressed in cancer cells and low iron
levels are not attributed to increased iron export but to higher
consumption. However, we found significantly reduced Fpn
mRNA levels in tumor samples from CCA patients compared to
matched surrounding liver, suggesting that also in PLC elevated
iron content is a negative prognostic factor (51).
The reprogramming of iron metabolism in tumors comprises
the repression of the iron storage protein ferritin, as a mean to
increase iron availability for the high requirements of cancer cell
(58). Conversely, a tumor-suppressive role for ferritin has been
shown in several types of cancer, such as breast and colorectal
cancer. Ferritin expression appears to be directly modulated
by both oncogenes, which down-regulate ferritin, and tumor
suppressors, which induce ferritin expression [reviewed in Torti
(39)]. Accordingly, a recent study highlighted a new mechanism
based on a complex miRNA network by which oncogenic
miRNAs inhibit the expression of H ferritin and its pseudogenes,
thus leading to prostate cancer growth (59). Ferritin expression
in liver cancer has been investigated by a number of studies in
rodent models of hepatocarcinogenesis and in human hepatomas
(60), but a coherent picture has not emerged, probably as the
result of different experimental approaches and models, but also
because of the multiple mechanisms of regulation of this protein,
which is affected by iron status, differentiation, growth rate,
inflammation, etc. (61). Therefore, whether increased ferritin
levels in HCC patients merely reflect increased accumulation of
iron, which is the actual carcinogen, or play an active role in
malignant transformation is still unknown.
LIVER CSC AND IRON
Over the last years, several investigations found increased iron
content in CSC of several types of tumors and also showed
that altered iron trafficking is functional to the role of CSC in
tumor growth. Indeed, variations of iron levels in CSC were
achieved by specific modulation of the expression of genes of iron
metabolism; in particular, TfR1-dependent iron uptake is induced
whereas Fpn-mediated iron export is down-modulated. In most
studies, the enhanced iron content was mirrored by high levels of
the iron storage protein ferritin (4, 62).
Support to the idea that higher iron levels have a functional
role in CSC formation and the maintenance of stemness
was provided by evidence that iron chelation inhibited tumor
spheres (a proxy of CSC) formation in several types of cancers
(4). Additionally, manipulation of iron levels modulated the
expression of typical stemness markers (4). Of course, it is also
conceivable that alterations of iron homeostasis induced by genes
related to CSC, such as Myc-mediated inhibition of ferritin
expression (63), cooperate in order to disrupt iron homeostasis
in CSC.
Notably, in vivo studies showing higher tumorigenic capacity
of iron-rich tumor spheres in mouse xenograft tumor models
confirmed the role of iron (64–66). Moreover, poorer prognosis
for human tumors with altered expression of iron proteins in CSC
is a common finding (51, 64, 66–68).
As it regards the role of iron in liver CSC, knowledge
is limited. We recently showed that the regulation of iron
homeostasis is profoundly different if CCA cell lines are cultured
under conditions inducing the formation of tumor spheres, as
compared to CCA cells growing in monolayers. In particular, we
found high H ferritin levels and TfR1 expression accompanied by
diminished Fpn transcription, a pattern leading to elevated iron
content. Moreover, this finding was mirrored by data showing
a trend toward shorter survival in CCA patients with high
expression of ferritin and hepcidin (51).
IRON AND CANCER THERAPY
In consideration of the role of iron in cancer, and particularly in
CSC that are resistant to radio and chemotherapy, manipulation
of iron levels appears a promising therapeutic strategy. Given
the double-edged sword property of iron in controlling cell
fate (Figure 1), both iron chelation (in order to starve tumor
cells for this essential micronutrient) and iron overload (in
order to exploit iron toxicity) have been proposed for cancer
treatment, but there are still several concerns for the use
of both strategies. In fact, the threshold above which iron
levels are no longer supportive of growth but become toxic
is not well-defined, even though recent findings indicated that
the functional iron concentration that allows in vitro cell
proliferation is very low (i.e., in the nanomolar range) (69). Iron
chelation has been used in several types of cancer, including
HCC (70). However, since desferrioxamine, an iron chelator
in use since the nineties, has a rather poor bioavailability,
limited success in treating cancer has been obtained with
iron chelators so far, though more recently developed oral
iron chelators like deferasirox showed some effect in leukemia
patients (71). The major mechanisms by which sequestration
of intracellular iron by classical iron chelators targets tumor
cells are:(i) inhibition of the iron-containing ribonucleotide
reductase, the rate-limiting enzyme for DNA synthesis, (ii) cyclin
dependent kinases-mediated induction of cell cycle arrest, iii)
activation of metastasis and tumor suppressor genes, such as
NDRG1 and p53, respectively. Moreover, recent data indicate
that chelators can also suppress cancer by inhibiting the EMT,
a key characteristic of CSC (72). Since the prolyl hydroxylases
controlling the levels of the hypoxia inducible factors (HIF)
are iron dependent enzymes, iron chelators induce HIF and
its numerous target genes (73). We have shown that HIF-1 is
involved in the protective effect exerted by the iron chelator
dexrazoxane against anthracycline cardiotoxicity (74). Therefore,
one may legitimately wonder whether iron chelators may have a
similar effect in cancer cells, thus limiting the therapeutic effect
of anticancer drugs.
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A new class of iron chelators, such as the thiosemicarbazone
Dp44m, which were reported to inhibit the proliferation of
cancer cell lines in vitro by inducing the expression of p21, a
cyclin-dependent kinase inhibitor involved in cell cycle arrest
(75), appear promising. Opposite to conventional iron chelators
like desferrioxamine, Dp44m is a tridentate ligand that forms
redox active iron complexes leading to increased oxidant levels
and cytotoxicity (76). These compounds also limit the growth of
tumor xenografts in nude mice and have entered clinical trials,
but their effect on CSC has not been tested. However, considering
the well-known drug resistance of CSC, it is worth to mention
that lysosomal-targeted Dp44m prevents the sequestration of a
chemotherapeutic anthracycline like doxorubicin in lysosomes,
which is triggered by the stressful environment of the tumor (77).
Through this mechanism, which allows doxorubicin to exert its
toxic effects in the nucleus and the mitochondria, this chelator
may thus favor the action of anticancer drugs. In the same line,
a recent study showed that a novel iron chelator, DpdtC (di-2-
pyridylketone hydrazone dithiocarbamate) can induce lysosomal
oxidant production and growth inhibition of HCC cell lines (78).
The use of these compounds represents therefore an approach
similar to that relying on the toxic side of iron for killing
cancer cells (see below). This strategy gained momentum after
the discovery of ferroptosis, a form on non-apoptotic cell
death caused by iron-dependent production and accumulation
of reactive and toxic hydroperoxides (79). Iron plays a dual
role in ferroptosis, as iron on the one hand can promote
Fenton chemistry and on the other hand stimulate the activity
of the iron-dependent enzyme lipoxygenases that contribute to
ferroptosis by degrading polyunsaturated fatty-acid-containing
phospholipids (80). Malignant cells generate high levels of
oxidants as by-products of the biosynthesis of macromolecules
and must balance iron uptake for proliferation with the risk of
generating oxidative stress (81). Since most ferroptosis-inducing
agents have limited use in vivo due to low bioavailability (82), iron
may thus have potential to trigger ferroptotic cell death in cancer,
as high iron concentrations may push malignant cells beyond the
breaking point of oxidative stress tolerance (34). Interestingly, it
has been shown that iron is required to induce ferroptosis also in
drug-resistant “persister” cancer cells, thus showing therapeutic
promise to eliminate this pool of tumor cells characterized by
non-mutational drug-tolerance (83).
Alternatively, iron may potentiate the effect of anticancer
drugs like the multikinase inhibitor sorafenib, which is used for
treating HCC. In fact, the evidence that iron chelation protected
HCC cells against iron-dependent oxidative stress caused by
sorafenib indicates that ferroptosis can represent an inhibitory
mechanism of the growth of liver cancer cells (84). A further
indication of the role of iron and ferroptosis in PLC was provided
by a study showing that ferritin induction protects HCC cells
from ferroptosis (85).
Triggering ferroptosis appears a promising approach also to
attack CSC, which represent a negative factor for cancer outcome
(86). Ovarian CSC showed higher sensitivity to ferroptosis
than non-tumorigenic ovarian stem cells (66) and a recent
study showed that in breast CSC exposure to salinomycin and
its derivatives leads to lysosomal iron accumulation, oxidants
production and ferroptosis (87). Similarly, increased intracellular
iron levels provided by ferritin degradation can lead glioblastoma
cells to ferroptosis (64). However, a number of recent studies
have shown that CSC are iron-rich and iron-dependent (4);
therefore, enhancing cellular iron may not always be an effective
strategy to eliminate CSC selectively. Moreover, in general,
low levels of oxidants have been reported in CSC, making
difficult the approach based on targeting iron-dependent, oxidant
related pathways in CSC. In fact, we found that sphere-forming
CCA cells, in spite of higher levels of oxidants and iron, were
more resistant to the ferroptosis inducer erastin than their
counterpart growing as monolayer (51). It seems therefore that,
before recommending the manipulation of iron homeostasis
as a therapeutic tool for targeting tumors and the use of
iron supplementation to promote ferroptosis of cancer cells,
additional studies are needed to understand the role of iron in
the pathways controlling cell death, as iron can possibly promote
CSC cell growth, thereby affecting the survival of cancer patients.
It should be also kept inmind that HCC almost always develop
in the context of chronic liver disease characterized by persistent
damage and inflammation, which can be further stimulated by
iron supplementation.
TARGETING IRON TO CANCER CELLS
Administration of massive quantities of iron successfully killed
multiple myeloma cells (88), though these cells, which secrete
large amounts of disulfide-rich immunoglobulins and are thus
a source of oxidants (89), may be particularly sensitive to iron-
dependent oxidative stress. Iron may also mediate the effect
of high i.v. doses of vitamin C that were reported to kill
liver CSC specifically both in vitro and in vivo by promoting
oxidant production (90). This paradoxical effect of a recognized
antioxidant may be explained by the strong reducing properties
of ascorbic acid which, at pharmacological concentrations
(>1mM), maintains iron in the highly reactive ferrous form,
thereby increasing, instead of preventing, oxidative stress and
cell death.
How to load cancer cells, in particular CSC, with iron in vivo,
possibly in a specific way ? Oral iron is poorly adsorbed and its
uptake is subjected to a strict feed-back regulation (91), therefore,
even recurring to novel nanoparticulate ferritin core mimetics
(92), it does not appear a promising approach. Parenteral iron
preparations, such as dextran iron, have higher efficacy but
relatively poor safety due to hypersensitivity reactions. However,
new formulations, such as iron gluconate and iron sucrose,
do not present toxicity issues and two iv iron compounds
prepared with new pharmaceutical technologies are currently
approved for the treatment of iron deficiency anemia (93)
and could be used in cancer patients. These iron complexes
are endocytosed and processed by macrophages within the
reticuloendothelial system, mainly in the liver, spleen and
bone marrow, but the precise mechanism of recognition and
internalization is not fully defined (94). Inside the macrophages,
iron is released from the iron–carbohydrate complex in acidic
endo-lysosomes through a mechanism incompletely understood
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and subsequently transported to the cytoplasm, where it
can be stored in ferritin or exported into the bloodstream
by Fpn.
An approach alternative to exogenous iron administration
is to impair safe intracellular iron storage, for example by
triggering lysosomal ferritin degradation. Indeed, treatment of
breast CSC with salinomycin resulted in increased ferritin
degradation in lysosomes; the iron released then facilitated
oxidants production and ferroptosis (87). An analogous release
of catalytic ferrous iron from ferritin led mesothelioma cells to
death after exposure to non-thermal plasma, which produces
hydroxyl radicals (95). Similarly, artesunate, by enhancing
lysosomal ferritin degradation, was able to induce cell death in
HCC cell lines (96). Notably, regulated autophagic degradation
of ferritin (ferritinophagy) contributes to ferroptosis and was
found to occur in primary human hepatic stellate cells obtained
from liver tissue of advanced fibrotic patients with HCC, thereby
alleviating liver fibrosis (97). However, ferritin is not only, or not
always, a source of iron for Fenton chemistry. Iron storage inside
ferritin is a protective stratagem against iron-mediated oxidative
injury (34, 61) and also mitochondrial ferritin shields this
important organelle from oxidants damage (98). The relevance
of this function in cancer has been shown by a study reporting
that high ferritin expression in myeloma cells is directly related
to increased resistance to oxidants generated by exposure to the
proteasome inhibitor bortezomib (88). A similar effect was found
in HCC cells in which oxidative stress mediated induction of
ferritin protected from ferroptosis (85).
The alterations of iron homeostasis seem to involve not
only cancer cells, but also other cell types of the tumor
microenvironment, particularly macrophages. In response to
signals in the tumor microenvironment, tumor-associated
macrophages (TAM), which favor tumor growth and
progression, often become similar to M2 polarized macrophages
endowed with anti-inflammatory activity, which display a gene
expression profile characterized by active iron uptake and release
and ferritin repression (99, 100). Therefore, this kind of iron
metabolism in TAM macrophages might promote tumor growth
by providing iron to adjacent tumor cells (101). Notably, also
CCA CSC prime TAM toward a tumor-promoting phenotype,
although iron metabolism has not been explored in this setting
(24). However, it should be noted that the TAM population may
be heterogeneous (102), as it has been found that in one type of
murine prostate cancer, but not in another model of prostate
cancer, some TAM contain iron aggregates typical of iron storing
macrophages (103, 104) and in ovarian cancer TAM presented
a prevalence of M1 phenotype (105). In this case, TAM, by
sequestering iron, may limit its availability to cancer cells, thus
impairing tumor growth. On the other hand, accumulation of an
excess of exogenously administered iron, in the same way as an
excess of heme iron in hemorrhagic tumor regions (106), may
induce a switch of TAM toward the M1 antitumor phenotype,
which is associated with the most favorable prognosis, as recently
confirmed by extensive immunogenomic analysis of thousands
of diverse tumor types (102).
It should be noted that in malignancies induced (or
accompanied) by constant damage and chronic inflammation
like HCC, two factors can further impinge on iron trafficking: on
the one hand, TAM are more M1-like (107) and could restrict
iron availability in the microenvironment and exert toxicity
against malignant cells; on the other hand, the high hepcidin
levels caused by inflammation may weaken Fpn-mediated iron
release from macrophages, thus contrasting the iron-donating
activity of TAM. These considerations are at odd with the
correlation between high hepcidin levels and tumor progression
in breast cancer patients (108, 109) and poorer prognosis in CCA
(51). However, hepcidin may interact with Fpn expressed by both
TAM and cancer cells; moreover, other iron transporters like
lipocalin2 (110) may be involved.
While the role of iron in TAM, which seems clearly context-
dependent, remains to be fully clarified, iron handling by TAM
may have therapeutic implications. In fact, a seemingly promising
approach relies on the use of iron oxide nanoparticles, a type
of nanocarriers used for cancer targeted drug delivery, which
are internalized by macrophages, including TAM. In line with in
vitro data showing that superparamagnetic iron oxides induce a
macrophage shift from the M2 to the M1 subtype (111), a recent
study showed that iron oxide nanoparticles inhibited tumor
growth indirectly by inducing M1 polarization. Highly increased
iron levels in TAM resulted in oxidants production and cancer
cell apoptosis (112). While the specific targeting of some species
of drug delivering nanoparticles to tumors relies on the higher
permeability of leaky blood vessels inside the cancerous mass,
thanks to the magnetic properties of iron oxide nanoparticles,
a localized external magnetic field can be used to guide these
nanoparticles to tumors, thus achieving an improved therapeutic
response and reducing side effects.
CONCLUSIONS
There is growing evidence that iron homeostasis is dysregulated
in cancer, including PLC, and over the past few years also
insights into the key role of iron in CSC have emerged. CSC
show alterations of iron metabolism leading to a phenotype
characterized by elevated cellular iron content, so that the
expression of their typical features, such as stemness, is inhibited
by iron chelators, thus suggesting the use of these compounds
for CSC-targeted therapy. On the other hand, most recent
therapeutic approaches seem aimed at exploiting the capacity
of excess iron to induce ferroptotic cell death in cancer cells.
However, given the involvement of iron in many important
pathophysiological settings, it should be considered that we
need to better understand how manipulation of iron levels to
contrast tumor growth may interfere with iron homeostasis
in healthy tissues or worsen conditions accompanying cancer,
such as inflammation or anemia. Moreover, unfortunately, the
mechanism(s) underlying the redox regulation in CSC are still
not fully understood, as indicated by the higher resistance of
CCA CSC to ferroptosis despite a higher basal oxidative stress
condition (51).
Despite the still limited understanding of many processes,
the increasing recognition of the importance of iron in cancer
biology offers new chances to unravel tumor pathogenesis and
thus develop more effective iron-centered therapeutic strategies
against liver cancer.
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